NO327609B1 - Svekkede muterte bakterier anvendelige i vaksiner. - Google Patents

Svekkede muterte bakterier anvendelige i vaksiner. Download PDF

Info

Publication number
NO327609B1
NO327609B1 NO20004781A NO20004781A NO327609B1 NO 327609 B1 NO327609 B1 NO 327609B1 NO 20004781 A NO20004781 A NO 20004781A NO 20004781 A NO20004781 A NO 20004781A NO 327609 B1 NO327609 B1 NO 327609B1
Authority
NO
Norway
Prior art keywords
gene
bacteria
salmonella
mutation
vaccine
Prior art date
Application number
NO20004781A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004781L (no
NO20004781D0 (no
Inventor
Steven Neville Chatfield
Original Assignee
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptide Therapeutics Ltd filed Critical Peptide Therapeutics Ltd
Publication of NO20004781D0 publication Critical patent/NO20004781D0/no
Publication of NO20004781L publication Critical patent/NO20004781L/no
Publication of NO327609B1 publication Critical patent/NO327609B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C12N15/03Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/65Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
NO20004781A 1998-03-25 2000-09-25 Svekkede muterte bakterier anvendelige i vaksiner. NO327609B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9806449.6A GB9806449D0 (en) 1998-03-25 1998-03-25 Attenuated bacteria useful in vaccines
PCT/GB1999/000935 WO1999049026A1 (en) 1998-03-25 1999-03-25 Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines

Publications (3)

Publication Number Publication Date
NO20004781D0 NO20004781D0 (no) 2000-09-25
NO20004781L NO20004781L (no) 2000-11-08
NO327609B1 true NO327609B1 (no) 2009-08-31

Family

ID=10829280

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004781A NO327609B1 (no) 1998-03-25 2000-09-25 Svekkede muterte bakterier anvendelige i vaksiner.

Country Status (19)

Country Link
US (1) US6902906B1 (de)
EP (1) EP1066376B1 (de)
JP (1) JP4516210B2 (de)
KR (1) KR100628657B1 (de)
AT (1) ATE296881T1 (de)
AU (1) AU763683B2 (de)
CA (1) CA2323576C (de)
CZ (1) CZ301520B6 (de)
DE (1) DE69925585T2 (de)
DK (1) DK1066376T3 (de)
ES (1) ES2244182T3 (de)
GB (1) GB9806449D0 (de)
HU (1) HU225644B1 (de)
NO (1) NO327609B1 (de)
NZ (1) NZ507077A (de)
PL (1) PL196076B1 (de)
PT (1) PT1066376E (de)
WO (1) WO1999049026A1 (de)
ZA (1) ZA200004987B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
WO2002057780A1 (en) * 2001-01-18 2002-07-25 Newcastle University Ventures Ltd. Biosensor with covalently attached membrane-spanning proteins
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US7297338B2 (en) * 2003-05-14 2007-11-20 Wyeth Avian vaccine composition for the protection of poultry against disease and infection caused by E. coli and Salmonella
US7357935B2 (en) * 2003-05-14 2008-04-15 Wyeth Avian E. coli vaccine for protection against colibacillosis
CN101378780A (zh) * 2006-02-01 2009-03-04 Sbl疫苗公司 重组细菌中的肠产毒性大肠杆菌定居因子(cf)抗原
JP2008054614A (ja) * 2006-09-01 2008-03-13 Nippon Inst For Biological Science 鶏大腸菌由来弱毒変異株、鶏大腸菌対策用ワクチン、免疫方法及び鶏用ワクチンベクター
EP2857038B1 (de) 2006-09-18 2019-04-10 The Board of Trustees of the University of Arkansas Zusammensetzungen und Verfahren zur Verstärkung von Immunreaktionen
US9125854B2 (en) * 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT2214701T (pt) 2007-11-01 2016-11-02 Univ Guelph Composições e métodos de potenciar respostas imunes a eimeria
NO2525817T3 (de) 2010-01-21 2018-01-06
BR112012031211A2 (pt) 2010-06-09 2018-01-30 Univ Arkansas métodos e vacina para reduzir a infecção causada pelo campylobacter
WO2014037445A1 (en) * 2012-09-05 2014-03-13 Lohmann Animal Health Gmbh Preparation of live vaccines
CN104995292A (zh) 2012-12-07 2015-10-21 洛曼动物健康有限责任公司 活疫苗制备
EP2956165B1 (de) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Zusammensetzungen und verfahren zur verstärkung von immunreaktionen gegenüber eimeria oder zur begrenzung von eimeria-infektionen
CN105142653B (zh) 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
ATE111957T1 (de) * 1990-02-06 1994-10-15 Pasteur Institut Transformiertes shigella.
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
ATE180280T1 (de) * 1991-03-05 1999-06-15 Wellcome Found Expression rekombinanter proteine in attenuierten bakterien

Also Published As

Publication number Publication date
AU763683B2 (en) 2003-07-31
EP1066376A1 (de) 2001-01-10
DK1066376T3 (da) 2005-10-03
JP4516210B2 (ja) 2010-08-04
PT1066376E (pt) 2005-10-31
HUP0105430A2 (hu) 2002-04-29
NZ507077A (en) 2002-10-25
CA2323576A1 (en) 1999-09-30
JP2002507414A (ja) 2002-03-12
HU225644B1 (en) 2007-05-02
DE69925585D1 (de) 2005-07-07
PL343246A1 (en) 2001-07-30
CA2323576C (en) 2010-12-07
PL196076B1 (pl) 2007-12-31
ATE296881T1 (de) 2005-06-15
NO20004781L (no) 2000-11-08
KR100628657B1 (ko) 2006-09-26
KR20010042175A (ko) 2001-05-25
ZA200004987B (en) 2001-10-31
CZ20003470A3 (cs) 2001-07-11
DE69925585T2 (de) 2006-07-13
WO1999049026A1 (en) 1999-09-30
ES2244182T3 (es) 2005-12-01
HUP0105430A3 (en) 2004-10-28
US6902906B1 (en) 2005-06-07
GB9806449D0 (en) 1998-05-27
EP1066376B1 (de) 2005-06-01
AU3045899A (en) 1999-10-18
NO20004781D0 (no) 2000-09-25
CZ301520B6 (cs) 2010-03-31

Similar Documents

Publication Publication Date Title
US6399074B1 (en) Live attenuated salmonella vaccines to control avian pathogens
EP1066376B1 (de) Bakterien abgeschwächt durch einen nicht revertierende mutation in jeden der aroc, ompf und ompc gene, verwendbar als impstoff
CA2244807A1 (en) Salmonella typhimurium vaccine
Ahmed et al. Protection of adult rabbits and monkeys from lethal shigellosis by oral immunization with a thymine-requiring and temperature-sensitive mutant of Shigella flexneri Y
HU217776B (hu) Élő vakcina, és a hatóanyagot képező gyengített baktérium, valamint eljárás ezek előállítására
DK2879700T3 (en) Hitherto unknown live attenuated Shigella vaccine
Dilts et al. Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity
Su et al. Regulated delayed Shigella flexneri 2a O-antigen synthesis in live recombinant Salmonella enterica serovar Typhimurium induces comparable levels of protective immune responses with constitutive antigen synthesis system
Newland et al. Genotypic and phenotypic characterization of an aroD deletion-attenuated Escherichia coli K12-Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen
Mills et al. Analysis and genetic manipulation of Shigella virulence determinants for vaccine development
US20230372462A1 (en) High dose shigella vaccine preparation
US6905691B1 (en) Vaccines containing attenuated bacteria
Zhao et al. Regulated delayed attenuation enhances the immunogenicity and protection provided by recombinant Salmonella enterica serovar Typhimurium vaccines expressing serovar Choleraesuis O-polysaccharides
EP1037664A1 (de) Impfstoffe die abgeschwächte bakterien enthalten
CN101730737A (zh) 超表达重组霍乱毒素b亚单位的霍乱弧菌显示双重免疫原性
MXPA00009354A (en) Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees